Quarterly ResultMay 7, 2026, 04:38 PM
Vaxart Q1 Net Income $5.18M; Revenue $39.23M, up 88%
AI Summary
Vaxart, Inc. reported a net income of $5.179 million for the first quarter of 2026, a substantial improvement from a $15.591 million loss in the same period last year. Total revenue for the quarter increased by 88% to $39.227 million, driven primarily by higher government contract revenue and new collaboration revenue. The company also announced an agreement in April 2026 to sell up to $25.0 million in common stock to Lincoln Park Capital, extending its cash runway into Q2 2027.
Key Highlights
- Net income of $5.179 million for Q1 2026, a significant improvement from a $15.591 million loss in Q1 2025.
- Total revenue increased 88% to $39.227 million in Q1 2026 from $20.876 million in Q1 2025.
- Revenue from government contracts rose to $36.370 million in Q1 2026 from $19.297 million in Q1 2025.
- Collaboration revenue was $2.815 million in Q1 2026, compared to none in Q1 2025.
- Basic earnings per share (EPS) was $0.02 for Q1 2026, up from $(0.07) in Q1 2025.
- Cash and cash equivalents stood at $50.746 million as of March 31, 2026.
- Entered an agreement in April 2026 to sell up to $25.0 million in common stock to Lincoln Park Capital.
- Company expects cash runway into the second quarter of 2027.
Price Impact
More from VXRT